Stocktoria
Inmune Bio, Inc. INMB
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2019-02-04
Inmune Bio, Inc. financials (annual)
Bars are annual figures from 2017 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $50,000 | $14,000 | $155,000 | $374,000 | $181,000 | $11,000 | — | $0 | $0 |
| R&D expense | $20.7M | $33.2M | $20.3M | $17.1M | $20.5M | $5.9M | $3.3M | $3.4M | $435,362 |
| Operating income | -$47.4M | -$42.6M | -$29.7M | -$26.0M | -$29.2M | -$12.2M | -$7.8M | -$12.4M | -$981,480 |
| Interest expense | — | $357,000 | $2.3M | $2.0M | — | — | — | — | — |
| Income tax | — | — | — | — | — | — | — | $0 | $0 |
| Net income | -$45.9M | -$42.1M | -$30.0M | -$27.3M | -$30.3M | -$12.1M | -$7.7M | -$12.4M | -$831,486 |
| EPS (diluted) | $-1.86 | $-2.11 | $-1.67 | $-1.52 | $-1.88 | — | — | — | — |
| Operating cash flow | -$22.6M | -$33.4M | -$12.0M | -$22.7M | -$28.5M | -$8.9M | -$5.4M | -$2.1M | -$761,834 |
| Free cash flow | -$23.6M | — | — | — | — | — | — | — | — |
| Cash & equivalents | $24.8M | $20.9M | $35.8M | $52.2M | $74.8M | $22.0M | $7.0M | $186,204 | $1.4M |
| Total assets | $32.4M | $39.6M | $57.0M | $81.8M | $99.9M | $40.7M | $24.5M | $17.4M | $18.4M |
| Total liabilities | $8.8M | $7.5M | $18.9M | $21.7M | $19.7M | $1.9M | $860,543 | $823,766 | $309,717 |
| Shareholders' equity | $23.5M | $32.1M | $37.3M | $60.1M | $80.2M | $38.8M | $23.6M | $16.5M | $18.1M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +257.1% | -91.0% | -58.6% | +106.6% | +1545.5% | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.